Tag: CELGZ

EWSI, CELGZ & Extended Watchlist

E-Waste Systems, Inc.  EWSI
–
We talked about EWSI on Friday, at which time it was trading at a low of .043, and have monitored the stock throughout this week. Yesterday, we saw a high of .0519, marking a 21% move off of the bottom. We wanted to see EWSI hold above its 50DMA (.045), and it has thus far managed to do so. Looking forward, we’d like to see the stock continue to hold above that level.

The company had some news out yesterday regarding plans for the opening of the largest e-waste facility in India:

LONDON, UNITED KINGDOM, Oct 08, 2013 (Marketwired via COMTEX) — E-Waste Systems, Inc. (OTCQB: EWSI) (‘EWSI’ or the “Company”), an electronic waste management services, technology and reverse logistics company and the first public pure eWaste company, announced today that it has signed an MOU with Cerebra Integrated Technologies Limited (‘Cerebra’), a publicly traded company listed on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). Cerebra, based in Bangalore, India is India’s leading total IT Solutions provider. The agreement calls for the creation, in Bangalore, of the largest E-Waste facility in India, using EWSI’s ePlant1000(TM) technology. The facility is expected to achieve at least 98% recovery of recyclable materials. An investment via a share exchange between the partners is also expected to form part of the relationship.

Celgene Corp. CELGZ
We were watching CELGZ yesterday due to abnormal pre-market activity, for the possibility of quick gains, and that’s just what we got. The stock, after touching a low of 1.39 rumbled upward to as much as 2.70, a 94% intraday gain. This came on roughly 33X the 3mo. average volume.

With that kind of momentum, it appears as if CELGZ’s success could spill over into today’s session, so we’ll want to keep this one high on our watchlists.

Extended Watchlist:

 ABIO, INO, AA, GOGO, PROP

ATOS, CTIC, APP & Extended Watchlists

Atossa Genetics, Inc.  ATOS
–
We tacked ATOS onto our extended watchlist yesterday morning, noting that the stock was in the midst of a “Huge gap down” and that we were “watching for a potential bounce”. Indeed that was the case, as the stock touched a low of 2.54 before a reversal carried it as high 3.18, a 25% intraday gain. As usual, when we see big gap-downs, we are looking out for quick-strike opportunities that allow us to make a rapid profit and a timely exit.We have uncovered a few other stocks fitting that profile that we will be monitoring for similar activity today:

Tower Group Intl. Ltd. TWGP

CEL-SCI Corp. CVM

Celgene Corp. CELGZ

Cell Therapeutics, Inc. CTIC
Another play from yesterday’s extended watchlist, CTIC opened at its low of day, and rumbled upward for a 23% move, closing at the high of day on nearly 12X its 3mo. average volume. In doing so, it managed to break a previous swing high at 1.80, a level we’d like to see hold as support moving forward.

We prepared the the following video chart on CTIC:

With the kind of momentum CTIC built up over the course of the day yesterday, this is one play that will be near the top of our watchlists in the near future. The catalyst here seems to be an agreement announced yesterday between the company and the FDA as outlined in the press release below.

SEATTLE, Oct. 7, 2013 /PRNewswire via COMTEX/ — Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced that the company reached agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for the planned pivotal Phase 3 clinical trial, known as the PERSIST-2 trial, evaluating pacritinib compared to best available therapy, including approved JAK2 inhibitors such as ruxolitinib, in patients with myelofibrosis whose platelet counts are <100,000/uL. The SPA is a written agreement between CTI and the FDA regarding the design, endpoints and planned statistical analysis approach of the trial to be used in support of a potential New Drug Application (NDA) submission. The PERSIST-2 trial is the second of two planned Phase 3 clinical trials in patients with myelofibrosis. CTI expects to initiate the PERSIST-2 clinical trial in the fourth quarter of 2013. >>> FULL STORY

American Apparel, Inc. APP

APP is another stock we have tracked for an extended period of time. We have been watching this one to sniff out a bottom for the past few months, and wanted to re-enter it into the conversation today, as that point may be drawing near. A quick peek at the chart below clearly shows just that:

Extended Watchlist:

JCP, AGEN, CBMX, NAVB, TKMR

GRNH, CBIS, ERBB & Today’s Extended Watchlist

GreenGro Technologies, Inc. GRNH

We’ve often used the old term “If it ain’t broke, don’t fix it” around here, and it certainly seems to apply to our medical marijuana plays. We continue to see these high-flyers churning out sizable gains, time and again.

Friday was another monumental session for our watchlist with both GRNH, and CBIS trading record volume. With that surge in trading, came breakouts for both stocks.

GRNH was up another 183% on Friday, closing at .085. This represents a 554% gain from the low of .013 back when we first issued our med. marijuana report (Oct. 16).

While not the first gains we’ve seen from GRNH, Friday’s were the largest we’ve seen to this point, and on more than 10X its average volume.

Barchart.com is currently giving GRNH a “100% Buy” Rating.

We don’t think it is very likely to see a big pullback following that type of momentum, however, in the event of a consolidation, we’d like to see support hold in the .05-.06 range.

____

Cannabis Science, Inc. CBIS

As stated above, CBIS had record volume day on Friday. The video chart we put out that morning pointed to the fact that we wanted to see a break past the 200DMA of .07, and it happened that very same afternoon.

The stock went on to hit a high of .10, and closed out strong at .09. Being as low as .04 following our Oct 16th report, the gains at Friday’s high represent a 150% move.

Like GRNH, the momentum on CBIS was off the charts on Friday, therefore we anticipate some carry-over into today’s session.

____

Tranzbyte Corp ERBB

ERBB is one of the few cannabis-related stocks that is trading sub-penny. On Friday, the stock closed at a major resistance point of .004 (200DMA).

The stock has bumped its head against that point on quite a few occasions this year. Each time, it has been unsuccessful at getting over that obstacle.

Passing the 200DMA would be a major push in the right direction for ERBB, and would open the door for its next leg up. We’ll be continuing to monitor the stock for just such an eventuality.

____
Extended Watchlist:

STLK, CGRA, ACGX, LUNL, CELGZ, INO,